T2 Biosystems has multiple diagnostic applications in development, all designed to enable further breakthroughs in rapid and accurate therapy for patients. The diagnostics are focused on critical, unmet needs in healthcare, where solutions can serve a dual role of improving patient care while reducing costs.
T2Carba Resistance+™ Panel: T2 Biosystems has partnered with Allergan and CARB-X to develop panels with additional bacterial species and resistance markers. The T2Carba Resistance+ Panel detects gram-negative resistance markers and is expected to be available for research use only in the first half of 2019.
T2Lyme™ Panel: T2 Biosystems and Canon U.S. Life Sciences have partnered to develop a panel to diagnose Lyme disease with greater accuracy. T2 Biosystems is currently enrolling patients in an FDA clinical trial for the T2Lyme Panel to evaluate the clinical performance of T2Lyme compared to skin biopsy and/or detection of the C6 antigen. The clinical trial will continue in 2019.*
T2Candida auris™ Panel RUO: Direct detection of the emerging superbug Candida auris in patient skin and blood samples and hospital environmental samples are now available for research use only (RUO) assays. The CDC** validated the T2Candida auris Panel RUO swab test on patient skin samples and published their 2017 findings in Mycoses.1